Charles River Laboratories Announces First-Quarter 2016 Results from Continuing Operations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Charles River Laboratories (CRL) PT Increases to $83 - UBS
May 5, 2016 9:00 AM EDTUBS analyst, Jonathan Groberg, raised his PT on Charles River Labs (NYSE: CRL) to $83 from $76 but maintained his Neutral rating after 1Q16 beats and management raises full year EPS guidance. Revenue of $355m was in-line with consensus estimates and EPS of $0.98 was above consensus estimates... More
Charles River Laboratories (CRL) Tops Q1 EPS by 8c; Boosts FY16 EPS Outlook
May 4, 2016 7:33 AM EDTCharles River Laboratories (NYSE: CRL) reported Q1 EPS of $0.98, $0.08 better than the analyst estimate of $0.90. Revenue for the quarter came in at $354.9 million versus the consensus estimate of $354.91 million.
GUIDANCE:
Charles River Laboratories sees FY2016 EPS of $4.32-$4.45, versus the... More
